Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma
نویسندگان
چکیده
منابع مشابه
Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for a multitude of reasons including very late diagnosis. This in part is due to the lack of understanding of the biological behavior of PDAC and the ineffective screening for this disease. Significant efforts have been dedicated to finding the appropriate serum and imaging biomarkers to help early detection and predict response...
متن کاملMicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and few chemotherapeutic choices. MicroRNAs (miRNAs) are non-coding, single-stranded RNAs of around 22 nucleotides involved in the pathogenic mechanisms of carcinogenesis and metastasis. They have been studied in many tumors in order to identify potential diagnostic, prognostic or therapeutic target...
متن کاملBiomarkers in pancreatic adenocarcinoma.
Pancreatic adenocarcinoma is a highly aggressive cancer, with a median patient survival of less than one year. Clinically useful biomarkers capable of accurately assessing prognosis, as well as response to therapy, are urgently needed. At the 2014 ASCO Annual Meeting, Maus et al. (Abstract #e15199) and Neuzillet et al. (Abstract #e15200) present data on use of c-met as a prognostic biomarker, a...
متن کاملCancer Diagnostic and Predictive Biomarkers
1 Department of Experimental Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Napoli, Italy 2 Department of Microbiology and Immunology, Institute of Human Virology, Baltimore, MD 21201, USA 3Department of Research, International Prevention Research Institute, 69006 Lyon, France 4Department of Pathology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Napoli, Italy ...
متن کاملBiomarkers in pancreatic adenocarcinoma: current perspectives
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate of 7.7%. Most patients are diagnosed at an advanced stage not amenable to potentially curative resection. A substantial portion of this review is dedicated to reviewing the current literature on carbohydrate antigen (CA 19-9), which is currently the only guideline-recommended biomarker for PDAC. It provide...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Molecular Sciences
سال: 2017
ISSN: 1422-0067
DOI: 10.3390/ijms18030667